2018 Announcements

Appeal Upheld Against NICE Recommendation in England

10 October 2018

CLINUVEL PHARMACEUTICALS LTD today announced that the Appeal Panel of the National Institute of Health and Care Excellence (NICE) – the body responsible for providing evidence-based guidance on health and social care to the National Health Service (NHS) in England – has published a decision following an oral Appeal Hearing as part of the ongoing Highly Specialised Technology (HST) evaluation of CLINUVEL’s drug SCENESSE® (afamelanotide 16mg).

The Appeal Hearing, requested by CLINUVEL and three other consultee organisations representing erythropoietic protoporphyria (EPP) patients and expert physicians, was held in London on 30 July in front of an independent Appeal Panel appointed by NICE. The Appeal Panel heard arguments from the four consultees against the decision of the HST Committee not to recommend SCENESSE® for use by the English NHS for adult patients with the rare metabolic disorder EPP, published in a Final Evaluation Document (FED) on 22 May 2018.

Download PDF for more

Go To Top